The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

Lenacapavir, the world's first twice-yearly HIV prevention shot, gets US FDA nod-offering a discreet, long-acting solution ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...

The United States Food and Drug Administration (FDA) has approved Lenacapavir (LEN), a long-acting injectable antiretroviral hailed as a breakthrough in HIV prevention. Experts in India have welcomed ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

FDA approval paves the way for the jab to roll out across the world. But with funding being slashed, will it get to the ...

The United States Food and Drug Administration (FDA) has approved long-acting injectable lenacapavir for HIV prevention. The ...

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...